|
|
|
| Public Sector Forged, Private Sector Tested With Renovaro BioSciences' Mark Dybul, M.D. | His extensive resume (including directing roles at the President's Emergency Plan for AIDS Relief and The Global Fund to Fight AIDS, Tuberculosis and Malaria) prepared Mark Dybul, MD, for the C-suite, which has dealt him an unfair share of unique adversity that's the stuff of a Dateline NBC episode. On Business of Biotech, the CEO of Renovaro BioSciences gets introspective on leadership forged in the fires of public service and battle-tested in the private sector. |
|
|
|
|
Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals Nana Collett, VP, program management at NervGen Pharma, and Thierry Bilbault, senior VP, tech ops, at Ardelyx, think about the future of working with CDMOs. |
|
|
|
Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape. |
|
|
|
Finding scientific talent is an arduous process, often stealing precious time from our calendars. Furthermore, hiring well doesn’t have to be left to chance. Try these specific actions to increase the odds. |
|
|
|
|
| The Annual Clinical Trials Roundup | Delve into in-depth analyses of key diseases, players, and geographies influencing the pharmaceutical industry through an overview of Phase 1–3 clinical trials initiated in 2022 across all therapeutic areas. |
|
|
|
|
|
Inside you will find more on: - Manufacturing Outlook
- Staffing Clinical Trials
- Next-Gen Viral Vectors
- Leadership
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
